CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 80 enrolled
Drug / intervention
eLIFEwithIBDbehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05405855
NCT05405855N/ACompleted

eLIFEwithIBD (Living With Intention, Fullness and Engagement With Inflammatory Bowel Disease): The Impact of an ICT-based Intervention on Physical and Mental Health

University of Coimbra·interventional·Posted Jun 6, 2022·Updated Nov 14, 2022

In Brief

A clinical study evaluating eLIFEwithIBD for Inflammatory Bowel Diseases. Completed, enrolled 80 participants across 1 site.

Detailed Summary

This study aims to test the acceptability and preliminary efficacy of an online intervention (eLIFEwithIBD) developed for people with inflammatory bowel disease (IBD). The eLIFEwithIBD intervention is an adaptation of the LIFEwithIBD program (delivered in an in-person group format; Trindade et al., 2021), being an ACT, mindfulness, and compassion-based intervention. The eLIFEwithIBD intervention comprises nine sessions focusing on education about IBD, the functioning of the mind, emotions, and fatigue; acceptance of internal experiences; willingness; emotion regulation; values clarification; committed action; mindfulness; compassion; and gratitude. These topics are addressed through videos with therapists, texts, and experiential exercises.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPortugal
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedJun 6, 2022
Enrollment StartJan 5, 2022
Primary CompletionAug 1, 2022
Study CompletionOct 15, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.1 years ago

Interventions

eLIFEwithIBDbehavioral

eLIFEwithIBD program is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients.